Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak

Shares of Moderna plunged 25% on Thursday following a potential leak of Phase 3 clinical trial data for its experimental cancer vaccine, setting off a sharp selloff that comes after Citigroup downgraded Moderna and said its initial positive vaccine results gave it an “unjustifiable” valuation. READ MORE: Stay Connected Forbes Breaking News on X: Forbes Breaking News on TikTok: More From Forbes: (Source: Forbes Breaking News | Region: Global)